AlzeCure Pharma
4.11.2021 10:21:53 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador11.8.2026 23:15:00 CEST | Press release
Doubles Fermi power to market to 4.8 gigawatts (GW) over the next ~30 months Build-Own-Operate-Transfer structure accelerates one of America's largest AI campus power programs - with no capital outlay by Fermi DALLAS, TX / ACCESS Newswire / August 11, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced the execution of a framework agreement with Hillcore Energy Capital Corporation ("Hillcore") under which Hillcore will finance, build, own and operate the Hillcore Power Center, an approximately 2.6 GW power complex at Fermi's Project Matador campus in Carson County, Texas, under a Build-Own-Operate-Transfer (BOOT) structure. The Hillcore Power Center will comprise approximately 2.5 GW of natural gas-fired generation, developed in phases, together with approximately 100 megawatts (MW) of solar generation and battery energy storage. Construction of the first power block, approximately 350 MW, will begin on execution of definitive ag
ePropelled to Increase Manufacturing Footprint with $60 Million in U.S. Government Funding to Strengthen U.S. Drone Propulsion Supply Chain11.8.2026 13:00:00 CEST | Press release
Expansion Increases Manufacturing Capacity by 4X and Positions ePropelled as a Leading Domestic Supplier of Advanced Dual-Use Electric Propulsion Systems COVENTRY, UK / ACCESS Newswire / August 11, 2026 / ePropelled, a leading U.S. manufacturer of advanced electric propulsion systems for uncrewed aerial vehicles, aerospace, defense, and commercial applications, today announced a major expansion of its manufacturing operations, increasing its production footprint from 20,000 square feet to 80,000 square feet. The expansion is supported by $60 million in government funding through the Department of War's Industrial Base Analysis and Sustainment program, reinforcing the nation's commitment to strengthening domestic manufacturing of mission-critical drone technologies and advanced dual-use propulsion systems. The expanded facility will increase ePropelled's propulsion system production capacity by more than 4X, enabling the company to meet rapidly growing demand from U.S. government progra
ePropelled to Increase Manufacturing Footprint with $60 Million in U.S. Government Funding to Strengthen U.S. Drone Propulsion Supply Chain11.8.2026 13:00:00 CEST | Press release
Expansion Increases Manufacturing Capacity by 4X and Positions ePropelled as a Leading Domestic Supplier of Advanced Dual-Use Electric Propulsion Systems COVENTRY, UK / ACCESS Newswire / August 11, 2026 / ePropelled, a leading U.S. manufacturer of advanced electric propulsion systems for uncrewed aerial vehicles, aerospace, defense, and commercial applications, today announced a major expansion of its manufacturing operations, increasing its production footprint from 20,000 square feet to 80,000 square feet. The expansion is supported by $60 million in government funding through the Department of War's Industrial Base Analysis and Sustainment program, reinforcing the nation's commitment to strengthening domestic manufacturing of mission-critical drone technologies and advanced dual-use propulsion systems. The expanded facility will increase ePropelled's propulsion system production capacity by more than 4X, enabling the company to meet rapidly growing demand from U.S. government progra
AI/ML Innovations' Subsidiary NeuralCloud Achieves ISO 13485:2016 (MDSAP) Certification11.8.2026 13:00:00 CEST | Press release
Quality Management System Certification Strengthens NeuralCloud's Regulatory Readiness for ECG Software-as-a-Medical-Device Platform TORONTO, ON / ACCESS Newswire / August 11, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has achieved ISO 13485:2016 certification under the Medical Device Single Audit Program ("MDSAP") for its quality management system. The certification, issued by TÜV USA, Inc., applies to NeuralCloud's quality management system for the design, development, production, and distribution of Software as a Medical Device ("SaMD") for ECG analysis, including advanced PQRST waveform delineation, interval computation, arrhythmia analytics, signal quality scoring, and artifact reporting. ISO 13485 is the internationally recognized qu
RollerAds Launches a Full-Cycle Ad Platform with Traffic, Offers, and Monetization in One Workspace11.8.2026 11:30:00 CEST | Press release
The updated platform unifies campaign management, CPA offers, and website monetization within a single dashboard to help users manage affiliate marketing activities more efficiently from one place. LIMASSOL, CY / ACCESS Newswire / August 11, 2026 / RollerAds announced the official launch of its new full-cycle advertising platform, designed to simplify digital advertising workflows by bringing the entire process into a single workspace. The new platform is now live at my.rollerads.com following several months of open beta testing and product refinement based on user feedback. "Our goal was to make affiliate marketing management simpler and more efficient," said Pierre Bertin, Head of International Business Development at RollerAds. "With the new platform, users can work with campaigns, CPA offers, and monetization tools in one dashboard without switching between multiple accounts or services." One dashboard for the entire advertising workflow The new RollerAds platform allows users to m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom